Autosomal Dominant Polycystic Kidney Clinical Trial
— REORIENTEDOfficial title:
Deciphering the Role of Thyroid Hormones in Autosomal Dominant Polycystic Kidney Disease
Verified date | March 2024 |
Source | Mario Negri Institute for Pharmacological Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic, rare and life-threatening disease, characterized by the pathological formation of multiple fluid-filled cysts that arise from renal tubules and alter kidney architecture and function. In most patients, the progressive deterioration of renal function ultimately leads to end-stage kidney disease (ESKD) and the need for dialysis or kidney transplantation. Save the conventional anti-hypertensive strategies, there are currently two disease-specific treatments for ADPKD (Tolvaptan and Octreotide-LAR). However, these drugs are only available to patients at high risk of progression to ESKD, while a remarkable number of ADPKD patients progress to ESKD despite the treatments. Cyst formation in ADPKD is determined by mutations in two genes encoding two transmembrane proteins: polycystin1 and polycystin2. The pathogenesis of the disease involves a series of phenotypic alterations, including the de-differentiation of epithelial cells, uncontrolled proliferation and abnormal secretion of fluids in the cysts, metabolic remodeling, all phenomena that lead to the progressive loss of renal structure and function . Therefore, to try to investigate the mechanisms of the disease, the investigators should go in search of pleiotropic molecules capable of simultaneously modulating structure, function and metabolism. Research done so far suggests that thyroid hormones (TH) may also act as pleiotropic modulators in the patho-biology of ADPKD. TH signals play a crucial role in the regulation of cell de-differentiation and cell cycle reactivation, as well as in the metabolism and evolution of cardiac and renal diseases. Interestingly, changes in TH levels have been detected in approximately 80% of patients with chronic renal failure (CKD), whereas patients with ADPKD show a higher incidence of clinical and subclinical hypothyroidism. Despite these evidences, the ability of TH to modulate anti-cystogenic and renoprotective processes in ADPKD has not yet been studied. The objective of this study is to determine the levels of THs in the serum of ADPKD patients with normal renal function and mild, moderate or severe renal dysfunction, and to correlate them with renal functional parameters.
Status | Completed |
Enrollment | 91 |
Est. completion date | March 25, 2024 |
Est. primary completion date | February 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Male and female =18 years old; 2. Diagnosis of ADPKD based on renal ultrasonography or genetic test; 3. Written informed consent Exclusion Criteria: 1. Diagnosis of Hashimoto's disease, hyperthyroidism or pituitary disease or any other condition undergoing levothyroxine replacement 2. Patient with hypothyroidism treated with drug therapy 3. Active treatment with Tolvaptan and/or Octreotide-LAR; 4. Regular treatment with amiodarone, lithium, interferon or immunosuppressive drugs including steroids; 5. Active malignancy or acute or chronic inflammatory disease, HIV; 6. Dialysis or kidney transplantation; 7. Diabetes mellitus; 8. Hypocaloric diet or current dietary approaches to obtain weight loss. 9. Legal incapacity or any evidence that the patient will not be able to understand the study aims and procedures. |
Country | Name | City | State |
---|---|---|---|
Italy | Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò" | Ranica | BG |
Lead Sponsor | Collaborator |
---|---|
Mario Negri Institute for Pharmacological Research |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum levels of total and free triiodothyronine (T3). | Once during the study. | ||
Primary | Serum levels of total and free L-thyroxine (T4). | Once during the study. | ||
Primary | Serum levels of total and free thyroid stimulating hormone (TSH). | Once during the study. | ||
Primary | Serum levels of total and free reverse T3 (rT3). | Once during the study. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Recruiting |
NCT03596957 -
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 4 | |
Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
Recruiting |
NCT05500157 -
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
|
N/A | |
Recruiting |
NCT04111692 -
A Prospective Observational Study of Foam Sclerotherapy .
|
||
Recruiting |
NCT04907799 -
Daily Caloric Restriction in ADPKD
|
N/A | |
Completed |
NCT05401409 -
Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
Terminated |
NCT03749447 -
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
|
Phase 3 | |
Recruiting |
NCT05228574 -
Treatment of Vascular Stiffness in ADPKD
|
Phase 4 | |
Completed |
NCT04908462 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03858439 -
Dietary Intervention in ADPKD on Tolvaptan
|
N/A | |
Recruiting |
NCT06391450 -
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
|
Phase 4 | |
Recruiting |
NCT05478083 -
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
|
Phase 2 | |
Completed |
NCT03102632 -
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05996731 -
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
|
N/A | |
Recruiting |
NCT06193616 -
Outcome of ADPKD With Octreotide LAR
|
||
Completed |
NCT03366337 -
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
|
Phase 2 | |
Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |